Arun K Ghosh

List of Publications by Citations

374 papers	15,989 citations	66 h-index	108 g-index
413 ext. papers	17,691 ext. citations	5.1 avg, IF	6.8 L-index

#	Paper	IF	Citations
374	-Symmetric chiral bis(oxazoline)-metal complexes in catalytic asymmetric synthesis. *Tetrahedron: Asymmetry*, **1998**, 9, 1-45		681
373	Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. *Science* , **2000**, 290, 150-3	33.3	668
372	Organic carbamates in drug design and medicinal chemistry. *Journal of Medicinal Chemistry*, **2015**, 58, 2895-940	8.3	346
371	Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. *Antimicrobial Agents and Chemotherapy*, **2003**, 47, 3123-9	5.9	318
370	A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 16119-24	11.5	295
369	BACE1 (-secretase) inhibitors for the treatment of Alzheimer's disease. *Chemical Society Reviews*, **2014**, 43, 6765-813	58.5	232
368	Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS. *Journal of Medicinal Chemistry*, **2016**, 59, 5172-208	8.3	231
367	Structure-based design: potent inhibitors of human brain memapsin 2 (beta-secretase). *Journal of Medicinal Chemistry*, **2001**, 44, 2865-8	8.3	220
366	Design of Potent Inhibitors for Human Brain Memapsin 2 (-Secretase). *Journal of the American Chemical Society*, **2000**, 122, 3522-3523	16.4	219
365	The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity. *Biochemistry*, **2002**, 41, 9109-15	3.2	214
364	Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance. *Accounts of Chemical Research*, **2008**, 41, 78-86	24.3	212
363	Developing -secretase inhibitors for treatment of Alzheimer's disease. *Journal of Neurochemistry*, **2012**, 120 Suppl 1, 71-83	6	205
362	Crystal structure of memapsin 2 (beta-secretase) in complex with an inhibitor OM00-3. *Biochemistry* , **2002**, 41, 10963-7	3.2	184
361	High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. *Journal of Molecular Biology*, **2004**, 338, 341-52	6.5	182
360	Subsite specificity of memapsin 2 (beta-secretase): implications for inhibitor design. *Biochemistry*, **2001**, 40, 10001-6	3.2	179
359	Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV. *Bioorganic and Medicinal Chemistry*, **2007**, 15, 7576-80	3.4	158
358	beta-Secretase as a therapeutic target for Alzheimer's disease. *Neurotherapeutics*, **2008**, 5, 399-408	6.4	158

357	Total Synthesis of (±)-Ginkgolide B. *Journal of the American Chemical Society*, **1988**, 110, 649-651	16.4	156
356	Drug Development and Medicinal Chemistry Efforts toward SARS-Coronavirus and Covid-19 Therapeutics. *ChemMedChem*, **2020**, 15, 907-932	3.7	155
355	Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere. *Bioorganic and Medicinal Chemistry Letters*, **1998**, 8, 687-90	2.9	139
354	Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance. *Journal of Medicinal Chemistry*, **2006**, 49, 5252-61	8.3	131
353	Stereoselective photochemical 1,3-dioxolane addition to 5-alkoxymethyl-2(5H)-furanone: synthesis of bis-tetrahydrofuranyl ligand for HIV protease inhibitor UIC-94017 (TMC-114). *Journal of Organic Chemistry*, **2004**, 69, 7822-9	4.2	126
352	A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site. *Journal of Virology*, **2002**, 76, 1349-58	6.6	125
351	Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M. *Journal of Medicinal Chemistry*, **2006**, 49, 1379-87	8.3	119
350	Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114. *Journal of Molecular Biology*, **2006**, 363, 161-73	6.5	117
349	RING-CLOSING METATHESIS STRATEGY TO UNSATURATED □- AND □-LACTONES: SYNTHESIS OF HYDROXYETHYLENE ISOSTERE FOR PROTEASE INHIBITORS. *Tetrahedron Letters*, **1998**, 39, 4651-4654	2	111
348	Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. *Journal of Biological Chemistry*, **2007**, 282, 28709-28720	5.4	111
347	Total synthesis of microtubule-stabilizing agent (-)-laulimalide. *Journal of Organic Chemistry*, **2001**, 66, 8973-82	4.2	110
346	Enhancing protein backbone binding--a fruitful concept for combating drug-resistant HIV. *Angewandte Chemie - International Edition*, **2012**, 51, 1778-802	16.4	109
345	Synergistic effects of peloruside A and laulimalide with taxoid site drugs, but not with each other, on tubulin assembly. *Molecular Pharmacology*, **2006**, 70, 1555-64	4.3	107
344	Bis-tetrahydrofuran: a privileged ligand for darunavir and a new generation of hiv protease inhibitors that combat drug resistance. *ChemMedChem*, **2006**, 1, 939-50	3.7	100
343	In vivo inhibition of Abeta production by memapsin 2 (beta-secretase) inhibitors. *Journal of Neurochemistry*, **2004**, 89, 1409-16	6	100
342	Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors. *Journal of Medicinal Chemistry*, **2005**, 48, 6767-71	8.3	98
341	Severe acute respiratory syndrome coronavirus papain-like novel protease inhibitors: design, synthesis, protein-ligand X-ray structure and biological evaluation. *Journal of Medicinal Chemistry*, **2010**, 53, 4968-79	8.3	96
340	Beta-secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice. *FASEB Journal*, **2011**, 25, 775-84	0.9	93

339	Diastereofacial Selection in Nitrile Oxide Cycloaddition Reactions. The Anti-Directing Effect of an Allylic Oxygen and Some New Results on the Ring Metalation of Isoxazolines. A Synthesis of (±)-Blastmycinone. *Journal of Organic Chemistry*, **1984**, 49, 2762-2772	4.2	92
338	Syntheses of FDA Approved HIV Protease Inhibitors. *Synthesis*, **2001**, 2001, 2203-2229	2.9	91
337	Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation. *Journal of Medicinal Chemistry*, **1996**, 39, 3278-90	8.3	89
336	Design and synthesis of novel HIV-1 protease inhibitors incorporating oxyindoles as the P2'-ligands. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 1869-73	2.9	88
335	Total Synthesis of (-)-Laulimalide. *Journal of the American Chemical Society*, **2000**, 122, 11027-11028	16.4	88
334	Structure-based design, synthesis, and biological evaluation of a series of novel and reversible inhibitors for the severe acute respiratory syndrome-coronavirus papain-like protease. *Journal of Medicinal Chemistry*, **2009**, 52, 5228-40	8.3	86
333	Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro): IMPLICATIONS FOR nsp5 REGULATION AND THE DEVELOPMENT OF ANTIVIRALS. *Journal of Biological Chemistry*, **2015**, 290, 19403-22	5.4	85
332	Design, synthesis, and X-ray structure of potent memapsin 2 (beta-secretase) inhibitors with isophthalamide derivatives as the P2-P3-ligands. *Journal of Medicinal Chemistry*, **2007**, 50, 2399-407	8.3	85
331	N,N'-Disuccinimidyl Carbonate: A Useful Reagent for Alkoxycarbonylation of Amines. *Tetrahedron Letters*, **1992**, 33, 2781-2784	2	85
330	Enantioselective total synthesis of (+)-largazole, a potent inhibitor of histone deacetylase. *Organic Letters*, **2008**, 10, 3907-9	6.2	84
329	Enantioselective total synthesis of (+)-amphidinolide t1. *Journal of the American Chemical Society*, **2003**, 125, 2374-5	16.4	84
328	3-Tetrahydrofuran and pyran urethanes as high-affinity P2-ligands for HIV-1 protease inhibitors. *Journal of Medicinal Chemistry*, **1993**, 36, 292-4	8.3	83
327	Design, synthesis and antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 5684-8	2.9	82
326	Potent memapsin 2 (beta-secretase) inhibitors: design, synthesis, protein-ligand X-ray structure, and in vivo evaluation. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 1031-6	2.9	81
325	Conformationally Constrained Bis(oxazoline) Derived Chiral Catalyst : A Highly Effective Enantioselective Diels-Alder Reaction. *Tetrahedron Letters*, **1996**, 37, 3815-3818	2	81
324	Structure-based design of cycloamide-urethane-derived novel inhibitors of human brain memapsin 2 (beta-secretase). *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 15-20	2.9	80
323	Synthesis of Enantiomerically Pure Anti-Aldols: A Highly Stereoselective Ester-Derived Titanium Enolate Aldol Reaction. *Journal of the American Chemical Society*, **1996**, 118, 2527-2528	16.4	79
322	Structure-based design, synthesis, and biological evaluation of peptidomimetic SARS-CoV 3CLpro inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 5876-80	2.9	76

321	Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV. *ACS Chemical Biology*, **2015**, 10, 1456-65	4.9	75
320	Atomic resolution crystal structures of HIV-1 protease and mutants V82A and I84V with saquinavir. *Proteins: Structure, Function and Bioinformatics*, **2007**, 67, 232-42	4.2	74
319	SYNTHESIS AND OPTICAL RESOLUTION OF HIGH AFFINITY P-LIGANDS FOR HIV-1 PROTEASE INHIBITORS. *Tetrahedron Letters*, **1995**, 36, 505-508	2	74
318	In vitro selection of highly darunavir-resistant and replication-competent HIV-1 variants by using a mixture of clinical HIV-1 isolates resistant to multiple conventional protease inhibitors. *Journal of Virology*, **2010**, 84, 11961-9	6.6	73
317	Diastereoselection in Intermolecular Nitrile Oxide Cycloaddition (NOC) Reactions: Confirmation of the "Anti-Periplanar Effect" through a Simple Synthesis of 2-Deoxy-d-ribose. *Journal of the American Chemical Society*, **1982**, 104, 5788-5789	16.4	73
316	Urea Derivatives in Modern Drug Discovery and Medicinal Chemistry. *Journal of Medicinal Chemistry* , **2020**, 63, 2751-2788	8.3	73
315	Enantioselective synthesis of (-)-platensimycin oxatetracyclic core by using an intramolecular Diels-Alder reaction. *Organic Letters*, **2007**, 9, 4013-6	6.2	70
314	Beta-secretase as a therapeutic target for inhibitor drugs. *Current Medicinal Chemistry*, **2002**, 9, 1135-44	4.3	70
313	Total synthesis of (-)-platensimycin, a novel antibacterial agent. *Journal of Organic Chemistry*, **2009**, 74, 1163-70	4.2	69
312	Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir. *Journal of Molecular Biology*, **2008**, 381, 102-15	6.5	69
311	Laulimalide and paclitaxel: a comparison of their effects on tubulin assembly and their synergistic action when present simultaneously. *Molecular Pharmacology*, **2004**, 66, 113-21	4.3	69
310	SYNTHETIC STUDIES OF ANTITUMOR MACROLIDE LAULIMALIDE: ENANTIOSELECTIVE SYNTHESIS OF THE C-C SEGMENT BY A CATALYTIC HETERO DIELS-ALDER STRATEGY. *Tetrahedron Letters*, **1997** , 38, 2427-2430	2	68
309	Structure-based design of HIV-1 protease inhibitors: replacement of two amides and a 10 pi-aromatic system by a fused bis-tetrahydrofuran. *Journal of Medicinal Chemistry*, **1994**, 37, 2506-8	8.3	67
308	Design and synthesis of potent HIV-1 protease inhibitors incorporating hexahydrofuropyranol-derived high affinity P(2) ligands: structure-activity studies and biological evaluation. *Journal of Medicinal Chemistry*, **2011**, 54, 622-34	8.3	66
307	Structural locations and functional roles of new subsites S5, S6, and S7 in memapsin 2 (beta-secretase). *Biochemistry*, **2005**, 44, 105-12	3.2	66
306	Potent HIV protease inhibitors: the development of tetrahydrofuranylglycines as novel P2-ligands and pyrazine amides as P3-ligands. *Journal of Medicinal Chemistry*, **1993**, 36, 2300-10	8.3	66
305	Total synthesis and structural revision of (+)-amphidinolide W. *Journal of the American Chemical Society*, **2004**, 126, 3704-5	16.4	65
304	-1-Aminoindan-2-ol in Asymmetric Syntheses. *Synthesis*, **1998**, 1998, 937-961	2.9	65

303	Interchangeable SF3B1 inhibitors interfere with pre-mRNA splicing at multiple stages. *Rna*, **2016**, 22, 350-9	5.8	64
302	Enantioselective total synthesis of (-)-zampanolide, a potent microtubule-stabilizing agent. *Organic Letters*, **2011**, 13, 4108-11	6.2	64
301	ASYMMETRIC HETERO DIELS-ALDER REACTIONS OF DANISHEFSKY'S DIENE AND GLYOXYLATE ESTERS CATALYZED BY CHIRAL BISOXAZOLINE DERIVED CATALYSTS. *Tetrahedron: Asymmetry*, **1996**, 7, 2165-2168		63
300	Enantioselective total synthesis of peloruside A: a potent microtubule stabilizer. *Organic Letters*, **2008**, 10, 1001-4	6.2	62
299	A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 2143-55	5.9	62
298	Coronaviruses resistant to a 3C-like protease inhibitor are attenuated for replication and pathogenesis, revealing a low genetic barrier but high fitness cost of resistance. *Journal of Virology*, **2014**, 88, 11886-98	6.6	61
297	A stereoselective synthesis of (-)-tetrahydrolipstatin. *Chemical Communications*, **1999**, 1999, 1743-1744	5.8	60
296	Total Synthesis of (+)-Sinefungin. *Journal of Organic Chemistry*, **1996**, 61, 6175-6182	4.2	60
295	An Efficient Synthesis of Hydroxyethylene Dipeptide Isosteres: The Core Unit of Potent HIV-1 Protease Inhibitors. *Journal of Organic Chemistry*, **1991**, 56, 6500-6503	4.2	60
294	Prediction of potency of protease inhibitors using free energy simulations with polarizable quantum mechanics-based ligand charges and a hybrid water model. *Journal of Chemical Information and Modeling*, **2009**, 49, 2851-62	6.1	59
293	Design, synthesis and X-ray structure of protein-ligand complexes: important insight into selectivity of memapsin 2 (beta-secretase) inhibitors. *Journal of the American Chemical Society*, **2006**, 128, 5310-1	16.4	57
292	Counterions of BINAP-Pt(II) and -Pd(II) complexes: novel catalysts for highly enantioselective Diels-Alder reaction. *Organic Letters*, **1999**, 1, 2157-9	6.2	57
291	Total synthesis and revision of C6 stereochemistry of (+)-amphidinolide W. *Journal of Organic Chemistry*, **2006**, 71, 1085-93	4.2	55
290	A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication. *Nature Communications*, **2021**, 12, 668	17.4	55
289	Coherence between cellular responses and in vitro splicing inhibition for the anti-tumor drug pladienolide B and its analogs. *Journal of Biological Chemistry*, **2014**, 289, 1938-47	5.4	54
288	A stereoselective synthesis of (+)-herboxidiene/GEX1A. *Organic Letters*, **2011**, 13, 66-9	6.2	54
287	Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P1'-ligands to enhance backbone-binding interactions with protease: synthesis, biological evaluation, and protein-ligand X-ray studies. *Journal of Medicinal Chemistry*, **2009**, 52, 3902-14	8.3	54
286	Transition-State Mimetics for HIV Protease Inhibitors: Stereocontrolled Synthesis of Hydroxyethylene and Hydroxyethylamine Isosteres by Ester-Derived Titanium Enolate Syn and Anti-Aldol Reactions. *Journal of Organic Chemistry*, **1998**, 63, 6146-6152	4.2	54

285	P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines. *Biological and Pharmaceutical Bulletin*, **2009**, 32, 1588-93	2.3	53
284	Asymmetric Total Synthesis of the Gastroprotective Microbial Agent AI-77-B. *European Journal of Organic Chemistry*, **2003**, 2003, 821-832	3.2	53
283	Specificity of memapsin 1 and its implications on the design of memapsin 2 (beta-secretase) inhibitor selectivity. *Biochemistry*, **2002**, 41, 8742-6	3.2	53
282	Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors. *Journal of Medicinal Chemistry*, **2005**, 48, 3576-85	8.3	52
281	Enantioselective synthesis of (+)-cryptophycin 52 (LY355703), a potent antimitotic antitumor agent. *Journal of Organic Chemistry*, **2003**, 68, 9823-6	4.2	52
280	Joint X-ray/neutron crystallographic study of HIV-1 protease with clinical inhibitor amprenavir: insights for drug design. *Journal of Medicinal Chemistry*, **2013**, 56, 5631-5	8.3	51
279	Memapsin 2 (beta-secretase) inhibitors: drug development. *Current Alzheimer Research*, **2008**, 5, 121-31	3	51
278	Assignment of absolute stereochemistry and total synthesis of (-)-spongidepsin. *Organic Letters*, **2004**, 6, 2055-8	6.2	51
277	Total synthesis of antitumor depsipeptide (-)-doliculide. *Organic Letters*, **2001**, 3, 635-8	6.2	51
276	The Curtius rearrangement: mechanistic insight and recent applications in natural product syntheses. *Organic and Biomolecular Chemistry*, **2018**, 16, 2006-2027	3.9	49
275	Achmatowicz Reaction and its Application in the Syntheses of Bioactive Molecules. *RSC Advances*, **2016**, 6, 111564-111598	3.7	49
274	The development of cyclic sulfolanes as novel and high-affinity P2 ligands for HIV-1 protease inhibitors. *Journal of Medicinal Chemistry*, **1994**, 37, 1177-88	8.3	49
273	Tartaric Acid and Tartrates in the Synthesis of Bioactive Molecules. *Synthesis*, **2001**, 2001, 1281-1301	2.9	48
272	(-)-Doliculide, a new macrocyclic depsipeptide enhancer of actin assembly. *Journal of Biological Chemistry*, **2002**, 277, 32165-71	5.4	48
271	Asymmetric synthesis of (-)-tetrahydrolipstatin: an anti-aldol-based strategy. *Organic Letters*, **2000**, 2, 2405-7	6.2	48
270	Design and Development of Highly Potent HIV-1 Protease Inhibitors with a Crown-Like Oxotricyclic Core as the P2-Ligand To Combat Multidrug-Resistant HIV Variants. *Journal of Medicinal Chemistry*, **2017**, 60, 4267-4278	8.3	47
269	A mouse model for Betacoronavirus subgroup 2c using a bat coronavirus strain HKU5 variant. *MBio*, **2014**, 5, e00047-14	7.8	47
268	Enantioselective total synthesis of macrolide antitumor agent (-)-lasonolide A. *Organic Letters*, **2007**, 9, 1437-40	6.2	46

267	Enantioselective total synthesis of pladienolide B: a potent spliceosome inhibitor. *Organic Letters*, **2012**, 14, 4730-3	6.2	45
266	Peloruside B, a potent antitumor macrolide from the New Zealand marine sponge Mycale hentscheli: isolation, structure, total synthesis, and bioactivity. *Journal of Organic Chemistry*, **2010**, 75, 2-10	4.2	45
265	Mn(III)-PROMOTED ANNULATION OF ENOL ETHERS AND ESTERS TO FUSED OR SPIRO 2-CYCLOPENTENONES. *Tetrahedron Letters*, **1987**, 28, 175-178	2	45
264	Dimerization of HIV-1 protease occurs through two steps relating to the mechanism of protease dimerization inhibition by darunavir. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 12234-9	11.5	44
263	Selective inhibition of the West Nile virus methyltransferase by nucleoside analogs. *Antiviral Research*, **2013**, 97, 232-9	10.8	44
262	Bis(oxazoline) derived cationic aqua complexes: highly effective catalysts for enantioselective Diels-Alder reactions. *Tetrahedron: Asymmetry*, **1998**, 9, 3687-3691		44
261	Enantioselective total synthesis of +-jasplakinolide. *Organic Letters*, **2007**, 9, 2425-7	6.2	44
260	Asymmetric synthesis of anti-aldol segments via a nonaldol route: synthetic applications to statines and (-)-tetrahydrolipstatin. *Journal of Organic Chemistry*, **2009**, 74, 4508-18	4.2	43
259	Cyclic sulfolanes as novel and high affinity P2 ligands for HIV-1 protease inhibitors. *Journal of Medicinal Chemistry*, **1993**, 36, 924-7	8.3	43
258	Probing multidrug-resistance and protein-ligand interactions with oxatricyclic designed ligands in HIV-1 protease inhibitors. *ChemMedChem*, **2010**, 5, 1850-4	3.7	42
257	Development of protease inhibitors and the fight with drug-resistant HIV-1 variants. *Advances in Pharmacology*, **2008**, 56, 169-97	5.7	42
256	Highly Enantioselective Aldol Reaction: Development of a New Chiral Auxiliary from -1-Amino-2-hydroxyindan. *Journal of the Chemical Society Chemical Communications*, **1992**, 1992, 1673-1674		42
255	The Curtius Rearrangement: Applications in Modern Drug Discovery and Medicinal Chemistry. *ChemMedChem*, **2018**, 13, 2351-2373	3.7	42
254	Harnessing nature's insight: design of aspartyl protease inhibitors from treatment of drug-resistant HIV to Alzheimer's disease. *Journal of Medicinal Chemistry*, **2009**, 52, 2163-76	8.3	41
253	An enantioselective synthesis of the C-C segment of antitumor macrolide laulimalide. *Tetrahedron Letters*, **2000**, 41, 2319-2322	2	41
252	TOTAL SYNTHESIS OF GINKGOLIDE A. *Tetrahedron Letters*, **1988**, 29, 3205-3206	2	41
251	Structural evidence for effectiveness of darunavir and two related antiviral inhibitors against HIV-2 protease. *Journal of Molecular Biology*, **2008**, 384, 178-92	6.5	40
250	A Convergent, Enantioselective Total Synthesis of Streptogramin Antibiotic (-)-Madumycin II. *Journal of Organic Chemistry*, **1997**, 62, 7908-7909	4.2	39

249	Enantioselective syntheses of FR901464 and spliceostatin A: potent inhibitors of spliceosome. *Organic Letters*, **2013**, 15, 5088-91	6.2	38
248	Potent new antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease. *Journal of Medicinal Chemistry*, **2007**, 50, 4509-15	8.3	38
247	Potent HIV-1 Protease Inhibitors: Stereoselective Synthesis of a Dipeptide Mimic. *Journal of Organic Chemistry*, **1993**, 58, 1025-1029	4.2	38
246	Highly potent HIV-1 protease inhibitors with novel tricyclic P2 ligands: design, synthesis, and protein-ligand X-ray studies. *Journal of Medicinal Chemistry*, **2013**, 56, 6792-802	8.3	37
245	GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro. *Antimicrobial Agents and Chemotherapy*, **2009**, 53, 997-1006	5.9	37
244	An asymmetric total synthesis of brevisamide. *Organic Letters*, **2009**, 11, 4164-7	6.2	37
243	Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance. *Journal of Medicinal Chemistry*, **2009**, 52, 7689-705	8.3	37
242	ESTER DERIVED TITANIUM ENOLATE ALDOL REACTION: HIGHLY DIASTEREOSELECTIVE SYNTHESIS OF SYN- AND ANTI-ALDOLS. *Tetrahedron Letters*, **1997**, 38, 7171-7174	2	37
241	Cu(II)-catalyzed olefin migration and Prins cyclization: highly diastereoselective synthesis of substituted tetrahydropyrans. *Organic Letters*, **2011**, 13, 4328-31	6.2	36
240	Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies. *Journal of Medicinal Chemistry*, **2008**, 51, 6021-33	8.3	36
239	Total Synthesis of (+)-Polyoxin J. *Journal of Organic Chemistry*, **1999**, 64, 2789-2795	4.2	36
238	Conformations of laulimalide in DMSO-d6. *Journal of the American Chemical Society*, **2005**, 127, 12838-46	16.4	35
237	An enantioselective synthesis of the C-C segment of antitumor macrolide peloruside A. *Tetrahedron Letters*, **2003**, 44, 3967-3969	2	35
236	A stereoselective synthesis of (+)-boronolide. *Tetrahedron Letters*, **2000**, 41, 1003-1006	2	35
235	Two-Step Synthesis of Furans by Mn(III)-Promoted Annulation of Enol Ethers. *Chemistry Letters*, **1987**, 16, 223-226	1.7	35
234	Enantioselective total synthesis of (+)-lithospermic acid. *Organic Letters*, **2012**, 14, 5046-9	6.2	34
233	Tetrahydrofuran, tetrahydropyran, triazoles and related heterocyclic derivatives as HIV protease inhibitors. *Future Medicinal Chemistry*, **2011**, 3, 1181-97	4.1	34
232	Loss of protease dimerization inhibition activity of darunavir is associated with the acquisition of resistance to darunavir by HIV-1. *Journal of Virology*, **2011**, 85, 10079-89	6.6	34

231	Structure based design: novel spirocyclic ethers as nonpeptidal P2-ligands for HIV protease inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **1998**, 8, 979-82	2.9	34
230	GRL-0920, an Indole Chloropyridinyl Ester, Completely Blocks SARS-CoV-2 Infection. *MBio*, **2020**, 11,	7.8	34
229	The assembly-inducing laulimalide/peloruside a binding site on tubulin: molecular modeling and biochemical studies with [H]peloruside A. *Journal of Chemical Information and Modeling*, **2010**, 50, 2019-28	4.1	33
228	Asymmetric hetero Diels-Alder route to quaternary carbon centers: synthesis of (-)-malyngolide. *Tetrahedron Letters*, **2001**, 42, 6231-6233	2	33
227	Di(2-Pyridyl) Carbonate Promoted Alkoxycarbonylation of Amines: A Convenient Synthesis of Functionalized Carbamates. *Tetrahedron Letters*, **1991**, 32, 4251-4254	2	33
226	The structural evolution of -secretase inhibitors: a focus on the development of small-molecule inhibitors. *Current Topics in Medicinal Chemistry*, **2013**, 13, 1787-807	3	33
225	Enantioselective total syntheses of FR901464 and spliceostatin A and evaluation of splicing activity of key derivatives. *Journal of Organic Chemistry*, **2014**, 79, 5697-709	4.2	32
224	Asymmetric Aldol Route to Hydroxyethylamine Isostere: Stereoselective Synthesis of the Core Unit of Saquinavir. *Journal of Organic Chemistry*, **1997**, 62, 6080-6082	4.2	32
223	CYCLIC SULFONE-3-CARBOXAMIDES AS NOVEL P-LIGANDS FOR Ro 31-8959 BASED HIV-1 PROTEASE INHIBITORS. *Bioorganic and Medicinal Chemistry Letters*, **1995**, 5, 83-88	2.9	32
222	A Convergent, Enantioselective Total Synthesis of Hapalosin: A Drug with Multidrug-Resistance Reversing Activity. *Angewandte Chemie International Edition in English*, **1996**, 35, 74-76		32
221	Methods for Pyranoannulation: An Approach to a New Class of Polyethers. *Journal of Organic Chemistry*, **1985**, 50, 3017-3019	4.2	32
220	A novel central nervous system-penetrating protease inhibitor overcomes human immunodeficiency virus 1 resistance with unprecedented aM to pM potency. *ELife*, **2017**, 6,	8.9	31
219	CHEMOSELECTIVE CATALYTIC HYDROGENATION OF ALKENES BY LINDLAR CATALYST. *Tetrahedron Letters*, **1998**, 39, 947-948	2	31
218	Chelation-controlled reduction: stereoselective formation of syn-1,3-diols and synthesis of compactin and mevinolin lactone. *Journal of Organic Chemistry*, **2002**, 67, 8783-8	4.2	31
217	TiCl Promoted Three Component Coupling Reaction : A New Method for the Synthesis of Functionalized Tetrahydrofurans and Tetrahydropyrans. *Tetrahedron Letters*, **1999**, 40, 1083-1086	2	31
216	STEREOCONTROLLED SYNTHESIS OF HIV-l PROTEASE INHIBITORS WITH C-AXIS OF SYMMETRY. *Tetrahedron Letters*, **1991**, 32, 5729-5732	2	31
215	Structure-based design of highly selective -secretase inhibitors: synthesis, biological evaluation, and protein-ligand X-ray crystal structure. *Journal of Medicinal Chemistry*, **2012**, 55, 9195-207	8.3	30
214	Design of HIV-1 protease inhibitors with C3-substituted hexahydrocyclopentafuranyl urethanes as P2-ligands: synthesis, biological evaluation, and protein-ligand X-ray crystal structure. *Journal of Medicinal Chemistry*, **2011**, 54, 5890-901	8.3	30

213	Memapsin 2 (beta-secretase) inhibitor drug, between fantasy and reality. *Current Alzheimer Research*, **2007**, 4, 418-22	3	30
212	Stereoselective synthesis of pseudopeptide microbial agent AI-77-B. *Organic Letters*, **2001**, 3, 2677-80	6.2	30
211	Total Synthesis of Potent Antitumor Macrolide, (-)-Zampanolide: An Oxidative Intramolecular Cyclization-Based Strategy. *European Journal of Organic Chemistry*, **2012**, 2012, 4130-4139	3.2	29
210	Extreme multidrug resistant HIV-1 protease with 20 mutations is resistant to novel protease inhibitors with P1'-pyrrolidinone or P2-tris-tetrahydrofuran. *Journal of Medicinal Chemistry*, **2013**, 56, 4017-27	8.3	29
209	A symmetry-based concise formal synthesis of platencin, a novel lead against "superbugs". *Angewandte Chemie - International Edition*, **2009**, 48, 5372-5	16.4	29
208	TiCl4-promoted multicomponent reaction: a new entry to functionalized alpha-amino acids. *Organic Letters*, **2005**, 7, 7-10	6.2	29
207	Synthetic studies of microtubule stabilizing agent peloruside A: an asymmetric synthesis of C-C segment. *Tetrahedron Letters*, **2003**, 44, 7659-7661	2	29
206	P2' benzene carboxylic acid moiety is associated with decrease in cellular uptake: evaluation of novel nonpeptidic HIV-1 protease inhibitors containing P2 bis-tetrahydrofuran moiety. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 4920-7	5.9	28
205	Solution kinetics measurements suggest HIV-1 protease has two binding sites for darunavir and amprenavir. *Journal of Medicinal Chemistry*, **2008**, 51, 6599-603	8.3	27
204	Progress in Anti-SARS Coronavirus Chemistry, Biology and Chemotherapy. *Annual Reports in Medicinal Chemistry*, **2007**, 41, 183-196	1.6	27
203	Highly diastereoselective anti-aldol reactions utilizing the titanium enolate of cis-2-arylsulfonamido-1- acenaphthenyl propionate. *Organic Letters*, **2003**, 5, 1063-6	6.2	27
202	A convergent synthesis of (+)-cryptophycin B, a potent antitumor macrolide from Nostoc sp. cyanobacteria. *Organic Letters*, **2000**, 2, 1573-5	6.2	27
201	The Isoxazoline Route to □-Methylene Lactones. *Tetrahedron Letters*, **1983**, 24, 2623-2626	2	27
200	Design of substituted bis-Tetrahydrofuran (bis-THF)-derived Potent HIV-1 Protease Inhibitors, Protein-ligand X-ray Structure, and Convenient Syntheses of bis-THF and Substituted bis-THF Ligands. *ACS Medicinal Chemistry Letters*, **2011**, 2, 298-302	4.3	26
199	L-selectride-mediated highly diastereoselective asymmetric reductive aldol reaction: access to an important subunit for bioactive molecules. *Organic Letters*, **2008**, 10, 4811-4	6.2	26
198	Antiviral activity of UIC-PI, a novel inhibitor of the human immunodeficiency virus type 1 protease. *Antiviral Research*, **2002**, 54, 29-36	10.8	26
197	Novel HIV-1 protease inhibitors (PIs) containing a bicyclic P2 functional moiety, tetrahydropyrano-tetrahydrofuran, that are potent against multi-PI-resistant HIV-1 variants. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 1717-27	5.9	25
196	Stereoselective chloroacetate aldol reactions: syntheses of acetate aldol equivalents and darzens glycidic esters. *Organic Letters*, **2004**, 6, 2725-8	6.2	25

195	Synthetic studies of antitumor macrolide laulimalide: a stereoselective synthesis of the C-C segment. *Tetrahedron Letters*, **2000**, 41, 4705-4708	2	25
194	Insights into the mechanism of inhibition of CXCR4: identification of Piperidinylethanamine analogs as anti-HIV-1 inhibitors. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 1895-904	5.9	24
193	Novel P2 tris-tetrahydrofuran group in antiviral compound 1 (GRL-0519) fills the S2 binding pocket of selected mutants of HIV-1 protease. *Journal of Medicinal Chemistry*, **2013**, 56, 1074-83	8.3	24
192	A macrolactonization-based strategy to obtain microtuble-stabilizing agent (-)-laulimalide. *Tetrahedron Letters*, **2001**, 42, 3399-3401	2	24
191	HIGHLY STEREOSELECTIVE REDUCTION OF □-KETO ESTERS: UTILITY OF CIS-1-ARYLSULFONAMIDO-2-INDANOLS AS CHIRAL AUXILIARIES. *Tetrahedron Letters*, **1995**, 36, 6811-6814	2	24
190	Design of Highly Potent, Dual-Acting and Central-Nervous-System-Penetrating HIV-1 Protease Inhibitors with Excellent Potency against Multidrug-Resistant HIV-1 Variants. *ChemMedChem*, **2018**, 13, 803-815	3.7	23
189	Mechanism of Darunavir (DRV)'s High Genetic Barrier to HIV-1 Resistance: A Key V32I Substitution in Protease Rarely Occurs, but Once It Occurs, It Predisposes HIV-1 To Develop DRV Resistance. *MBio*, **2018**, 9,	7.8	23
188	Enantioselective total synthesis of macrolide (+)-neopeltolide. *Organic and Biomolecular Chemistry*, **2013**, 11, 7768-77	3.9	23
187	Capturing the essence of organic synthesis: from bioactive natural products to designed molecules in today's medicine. *Journal of Organic Chemistry*, **2010**, 75, 7967-89	4.2	23
186	Stereoselective synthesis of the C(1)-C(12) segment of iriomoteolide 1a: a very potent macrolide antitumor agent. *Tetrahedron Letters*, **2009**, 50, 1416-1418	2	23
185	A Stereoselective Anti-Aldol Route to (3,3a,6a)-Hexahydrofuro[2,3-] furan-3-ol: A Key Ligand for a New Generation of HIV Protease Inhibitors. *Synthesis*, **2006**, 2006, 3015-3018	2.9	23
184	Anharmonic modeling of the conformation-specific IR spectra of ethyl, n-propyl, and n-butylbenzene. *Journal of Chemical Physics*, **2016**, 144, 224310	3.9	23
183	Lasonolide A, a potent and reversible inducer of chromosome condensation. *Cell Cycle*, **2012**, 11, 4424-35	4.7	22
182	Enantioselective Synthesis of Spiro[cyclohexane-1,3'-indolin]-2'-ones Containing Multiple Stereocenters via Organocatalytic Michael/Aldol Cascade Reactions. *Tetrahedron Letters*, **2013**, 54, 2311-2314	2	22
181	Asymmetric alkylations and aldol reactions: (1,2)-2-aminocyclopentan-1-ol derived new chiral auxiliary. *Tetrahedron: Asymmetry*, **1997**, 8, 821-824		22
180	A short synthesis of (+/-)-eburnamonine. *Journal of Organic Chemistry*, **2000**, 65, 5433-5	4.2	22
179	Benzimidazole-Based FabI Inhibitors: A Promising Novel Scaffold for Anti-staphylococcal Drug Development. *ACS Infectious Diseases*, **2017**, 3, 54-61	5.5	21
178	GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 2036-46	5.9	21

177	INTRAMOLECULAR AND INTERMOLECULAR HYDROXYL REACTIVITY DIFFERENCES IN GINKGOLIDES A, B AND C AND THEIR CHEMICAL APPLICATIONS. *Tetrahedron Letters*, **1992**, 33, 6955-6958	2	21
176	**2014**,		20
175	GRL-04810 and GRL-05010, difluoride-containing nonpeptidic HIV-1 protease inhibitors (PIs) that inhibit the replication of multi-PI-resistant HIV-1 in vitro and possess favorable lipophilicity that may allow blood-brain barrier penetration. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 6110-21	5.9	20
174	Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 3460-70	5.9	20
173	Asymmetric dihydroxylation route to a dipeptide isostere of a protease inhibitor: enantioselective synthesis of the core unit of ritonavir. *Chemical Communications*, **1999**, 1999, 1025-1026	5.8	20
172	Structure-based design, synthesis, X-ray studies, and biological evaluation of novel HIV-1 protease inhibitors containing isophthalamide-derived P2-ligands. *Bioorganic and Medicinal Chemistry Letters*, **2015**, 25, 4903-4909	2.9	19
171	Total synthesis of GEX1Q1, assignment of C-5 stereoconfiguration and evaluation of spliceosome inhibitory activity. *Organic Letters*, **2014**, 16, 3154-7	6.2	19
170	Total synthesis of potent antitumor agent (-)-lasonolide A: a cycloaddition-based strategy. *Chemistry - an Asian Journal*, **2008**, 3, 1811-23	4.5	19
169	ASYMMETRIC DIELS-ALDER REACTION : CIS-1-ARYLSULFONAMIDO-2-INDANOLS AS HIGHLY EFFECTIVE CHIRAL AUXILIARIES. *Tetrahedron: Asymmetry*, **1996**, 7, 375-378		19
168	Design and Synthesis of Highly Potent HIV-1 Protease Inhibitors Containing Tricyclic Fused Ring Systems as Novel P2 Ligands: Structure-Activity Studies, Biological and X-ray Structural Analysis. *Journal of Medicinal Chemistry*, **2018**, 61, 4561-4577	8.3	19
167	X-ray structure and inhibition of the feline infectious peritonitis virus 3C-like protease: Structural implications for drug design. *Bioorganic and Medicinal Chemistry Letters*, **2015**, 25, 5072-7	2.9	18
166	Design of gem-difluoro-bis-tetrahydrofuran as P2 ligand for HIV-1 protease inhibitors to improve brain penetration: synthesis, X-ray studies, and biological evaluation. *ChemMedChem*, **2015**, 10, 107-15	3.7	18
165	Enantioselective Synthesis of Thailanstatin A Methyl Ester and Evaluation of in Vitro Splicing Inhibition. *Journal of Organic Chemistry*, **2018**, 83, 5187-5198	4.2	18
164	Defining Viral Defective Ribosomal Products: Standard and Alternative Translation Initiation Events Generate a Common Peptide from Influenza A Virus M2 and M1 mRNAs. *Journal of Immunology*, **2016**, 196, 3608-17	5.3	18
163	Design of the anti-HIV protease inhibitor darunavir **2013**, 355-384		18
162	Asymmetric multicomponent reactions: diastereoselective synthesis of substituted pyrrolidines and prolines. *Organic Letters*, **2006**, 8, 4509-11	6.2	18
161	Stereoselective construction of quaternary carbon centers by three component coupling reactions. *Tetrahedron Letters*, **2000**, 41, 8425-8429	2	18
160	A Facile and Enantiospecific Synthesis of 2()- and 2()-[1'()-Azido-2-phenylethyl]oxirane. *Journal of the Chemical Society Chemical Communications*, **1992**, 1992, 273-274		18

159	Structure-based design, synthesis and biological evaluation of novel β-secretase inhibitors containing a pyrazole or thiazole moiety as the P3 ligand. *Bioorganic and Medicinal Chemistry Letters*, **2015**, 25, 668-72	2.9	17
158	Structure-based design of potent HIV-1 protease inhibitors with modified P1-biphenyl ligands: synthesis, biological evaluation, and enzyme-inhibitor X-ray structural studies. *Journal of Medicinal Chemistry*, **2015**, 58, 5334-43	8.3	17
157	Enantioselective Synthesis of Both Epimers at C-21 in the Proposed Structure of Cytotoxic Macrolide Callyspongiolide. *Organic Letters*, **2016**, 18, 3274-7	6.2	17
156	Substituent effects on P2-cyclopentyltetrahydrofuranyl urethanes: design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 2308-11	2.9	17
155	Prospects of β-Secretase Inhibitors for the Treatment of Alzheimer's Disease. *ChemMedChem*, **2015**, 10, 1463-6	3.7	17
154	A Convenient Enzymatic Route to Optically Active l-Aminoindan-2-ol: Versatile Ligands for HIV-1 Protease Inhibitors and Asymmetric Syntheses. *Synthesis*, **1997**, 1997, 541-544	2.9	17
153	Convenient synthesis of novel macrocyclic urethanes: alkoxycarbonylation of amines and ring-closing metathesis strategy. *Tetrahedron Letters*, **1998**, 39, 1881-1884	2	17
152	TiC1 promoted three component coupling reaction: an efficient method for the substituted tetrahydropyrilidene acetates. *Tetrahedron Letters*, **1999**, 40, 4751-4754	2	17
151	Design and Synthesis of Potent HIV-1 Protease Inhibitors Containing Bicyclic Oxazolidinone Scaffold as the P2 Ligands: Structure-Activity Studies and Biological and X-ray Structural Studies. *Journal of Medicinal Chemistry*, **2018**, 61, 9722-9737	8.3	17
150	Indole Chloropyridinyl Ester-Derived SARS-CoV-2 3CLpro Inhibitors: Enzyme Inhibition, Antiviral Efficacy, Structure-Activity Relationship, and X-ray Structural Studies. *Journal of Medicinal Chemistry*, **2021**, 64, 14702-14714	8.3	17
149	Structural and biological evaluation of a novel series of benzimidazole inhibitors of Francisella tularensis enoyl-ACP reductase (FabI). *Bioorganic and Medicinal Chemistry Letters*, **2015**, 25, 1292-6	2.9	16
148	Design and synthesis of potent macrocyclic HIV-1 protease inhibitors involving P1-P2 ligands. *Organic and Biomolecular Chemistry*, **2014**, 12, 6842-54	3.9	16
147	Structure-based design, synthesis, and biological evaluation of dihydroquinazoline-derived potent β-secretase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 5460-5	2.9	16
146	Bifunctional cinchona alkaloid-squaramide-catalyzed highly enantioselective aza-Michael addition of indolines to α,β-unsaturated ketones. *Tetrahedron Letters*, **2013**, 54, 3500-3502	2	16
145	Synergistic inhibitor binding to the papain-like protease of human SARS coronavirus: mechanistic and inhibitor design implications. *ChemMedChem*, **2013**, 8, 1361-72	3.7	16
144	Enantioselective syntheses of the proposed structures of cytotoxic macrolides iriomoteolide-1a and -1b. *Organic Letters*, **2010**, 12, 3120-3	6.2	16
143	A convergent synthesis of the proposed structure of antitumor depsipeptide stereocalpin A. *Organic Letters*, **2009**, 11, 1963-6	6.2	16
142	Ester derived titanium enolate aldol reaction: chelation controlled diastereoselective synthesis of -aldols. *Tetrahedron Letters*, **2001**, 42, 1227-1231	2	16

141	MULTICOMPONENT REACTIONS: SYNTHESIS OF SPIROCYCLIC TETRAHYDROPYRAN DERIVATIVES BY PRINS CYCLIZATION. *Heterocycles*, **2002**, 58, 659-666	0.8	16
140	FeCl-Catalyzed Tandem Prins and Friedel-Crafts Cyclization: A Highly Diastereoselective Route to Polycyclic Ring Structures. *Tetrahedron Letters*, **2014**, 55, 4251-4254	2	15
139	Enantioselective synthesis of spliceostatin E and evaluation of biological activity. *Organic Letters*, **2014**, 16, 6200-3	6.2	15
138	Stereoselective Synthesis of Protected Thymine Polyoxin C via [2,3]-Wittig-Still Rearrangement of Ribose-Derived Allylic Stannyl Ethers. *Journal of Organic Chemistry*, **1998**, 63, 6735-6738	4.2	15
137	A conserved hydrogen-bonding network of P2 bis-tetrahydrofuran-containing HIV-1 protease inhibitors (PIs) with a protease active-site amino acid backbone aids in their activity against PI-resistant HIV. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 3679-88	5.9	14
136	Synthesis and biological evaluation of novel allophenylnorstatine-based HIV-1 protease inhibitors incorporating high affinity P2-ligands. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 1241-6	2.9	14
135	Potent HIV-1 protease inhibitors incorporating meso-bicyclic urethanes as P2-ligands: structure-based design, synthesis, biological evaluation and protein-ligand X-ray studies. *Organic and Biomolecular Chemistry*, **2008**, 6, 3703-13	3.9	14
134	Chelation-controlled ester-derived titanium enolate aldol reaction: diastereoselective -aldols with mono- and bidentate aldehydes. *Tetrahedron Letters*, **2002**, 43, 5621-5624	2	14
133	The Design, Development, and Evaluation of BACE1 Inhibitors for the Treatment of Alzheimer's Disease. *Topics in Medicinal Chemistry*, **2016**, 27-85	0.4	14
132	Enantioselective total synthesis and structural assignment of callyspongiolide. *Organic and Biomolecular Chemistry*, **2016**, 14, 11357-11370	3.9	13
131	Design, synthesis and in vitro splicing inhibition of desmethyl and carba-derivatives of herboxidiene. *Organic and Biomolecular Chemistry*, **2016**, 14, 5263-71	3.9	13
130	C-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, including Darunavir. *Journal of Virology*, **2015**, 90, 2180-94	6.6	13
129	Stereoselective synthesis of both tetrahydropyran rings of the antitumor macrolide, (-)-lasonolide A. *Journal of Organic Chemistry*, **2012**, 77, 2559-65	4.2	13
128	Stereoselective Synthesis of Dihydroisocoumarin Moiety of Microbial Agent AI-77-B: a Diels-Alder Based Strategy. *Tetrahedron Letters*, **1998**, 39, 8803-8806	2	13
127	Enantioselective Total Synthesis of (+)-Amphirionin-4. *Organic Letters*, **2016**, 18, 2296-9	6.2	13
126	Design of novel HIV-1 protease inhibitors incorporating isophthalamide-derived P2-P3 ligands: Synthesis, biological evaluation and X-ray structural studies of inhibitor-HIV-1 protease complex. *Bioorganic and Medicinal Chemistry*, **2017**, 25, 5114-5127	3.4	12
125	Design, synthesis, and X-ray structural studies of BACE-1 inhibitors containing substituted 2-oxopiperazines as P1'-P2' ligands. *Bioorganic and Medicinal Chemistry Letters*, **2017**, 27, 2432-2438	2.9	12
124	Design of HIV-1 Protease Inhibitors with Amino-bis-tetrahydrofuran Derivatives as P2-Ligands to Enhance Backbone-Binding Interactions: Synthesis, Biological Evaluation, and Protein-Ligand X-ray Studies. *Journal of Medicinal Chemistry*, **2015**, 58, 6994-7006	8.3	12

123	Enantioselective Syntheses of (-)-Alloyohimbane and (-)-Yohimbane by an Efficient Enzymatic Desymmetrization Process. *European Journal of Organic Chemistry*, **2016**, 2016, 6001-6009	3.2	12
122	A Tandem Olefin Migration and Prins Cyclization Using Cu(OTf)(2)-Bisphosphine Complexes: An Improved Synthesis of Functionalized Tetrahydropyrans. *Tetrahedron Letters*, **2012**, 53, 3699-3702	2	12
121	A stereoselective synthesis of (-)-viridiofungin A utilizing a TiCl(4)-promoted asymmetric multicomponent reaction. *Organic Letters*, **2012**, 14, 510-2	6.2	12
120	Synthesis and biological evaluation of new jasplakinolide (jaspamide) analogs. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 5104-7	2.9	12
119	Design and synthesis of stereochemically defined novel spirocyclic P2-ligands for HIV-1 protease inhibitors. *Organic Letters*, **2008**, 10, 5135-8	6.2	12
118	Enantioselective Synthesis of Cyclopentyltetrahydrofuran (Cp-THF), an Important High-Affinity P2-Ligand for HIV-1 Protease Inhibitors. *Tetrahedron Letters*, **2008**, 49, 3409-3412	2	12
117	The Development of Titanium Enolate-based Aldol Reactions63-125		12
116	Chiral Auxiliary Mediated Conjugate Reduction and Asymmetric Protonation: Synthesis of High Affinity Ligands for HIV Protease Inhibitors. *Journal of Organic Chemistry*, **1995**, 60, 6198-6201	4.2	12
115	Enantioselective Synthesis of Spliceostatin G and Evaluation of Bioactivity of Spliceostatin G and Its Methyl Ester. *Organic Letters*, **2018**, 20, 96-99	6.2	12
114	Drug Resistance Mutation L76V Alters Nonpolar Interactions at the Flap-Core Interface of HIV-1 Protease. *ACS Omega*, **2018**, 3, 12132-12140	3.9	12
113	Design of Potent and Highly Selective Inhibitors for Human β-Secretase 2 (Memapsin 1), a Target for Type 2 Diabetes. *Chemical Science*, **2016**, 7, 3117-3122	9.4	11
112	Activation of RAF1 (c-RAF) by the Marine Alkaloid Lasonolide A Induces Rapid Premature Chromosome Condensation. *Marine Drugs*, **2015**, 13, 3625-39	6	11
111	Potent antiviral HIV-1 protease inhibitor GRL-02031 adapts to the structures of drug resistant mutants with its P1'-pyrrolidinone ring. *Journal of Medicinal Chemistry*, **2012**, 55, 3387-97	8.3	11
110	TiCl4-promoted tandem carbonyl or imine addition and Friedel-Crafts cyclization: synthesis of benzo-fused oxabicyclooctanes and nonanes. *Organic Letters*, **2012**, 14, 2002-5	6.2	11
109	Highly diastereoselective synthesis of modified nucleosides via an asymmetric multicomponent reaction. *Chemical Communications*, **2010**, 46, 1218-20	5.8	11
108	Novel cyclourethane-derived HIV protease inhibitors: a ring-closing olefin metathesis based strategy. *Bioorganic and Medicinal Chemistry Letters*, **2002**, 12, 1993-6	2.9	11
107	An enantioselective synthesis of the core unit of the non-nucleoside reverse transcriptase inhibitor taurospongin A. *Tetrahedron: Asymmetry*, **2003**, 14, 629-634		11
106	S-adenosyl-homocysteine is a weakly bound inhibitor for a flaviviral methyltransferase. *PLoS ONE*, **2013**, 8, e76900	3.7	11

105	Probing Lipophilic Adamantyl Group as the P1-Ligand for HIV-1 Protease Inhibitors: Design, Synthesis, Protein X-ray Structural Studies, and Biological Evaluation. *Journal of Medicinal Chemistry* , **2016**, 59, 6826-37	8.3	11
104	Enantioselective Synthesis of a Cyclopropane Derivative of Spliceostatin A and Evaluation of Bioactivity. *Organic Letters*, **2018**, 20, 7293-7297	6.2	11
103	GRL-09510, a Unique P2-Crown-Tetrahydrofuranylurethane -Containing HIV-1 Protease Inhibitor, Maintains Its Favorable Antiviral Activity against Highly-Drug-Resistant HIV-1 Variants in vitro. *Scientific Reports*, **2017**, 7, 12235	4.9	10
102	Design, synthesis, biological evaluation and X-ray structural studies of HIV-1 protease inhibitors containing substituted fused-tetrahydropyranyl tetrahydrofuran as P2-ligands. *Organic and Biomolecular Chemistry*, **2015**, 13, 11607-21	3.9	10
101	Stereoselective Synthesis of Substituted Oxocene Cores by Lewis Acid Promoted Cyclization. *Organic Letters*, **2016**, 18, 396-9	6.2	10
100	Differentiating Isomeric Deprotonated Glucuronide Drug Metabolites via Ion/Molecule Reactions in Tandem Mass Spectrometry. *Analytical Chemistry*, **2018**, 90, 9426-9433	7.8	10
99	An Enantioselective Synthesis of a MEM-Protected Aetheramide A Derivative. *Tetrahedron Letters*, **2014**, 55, 5191-5194	2	10
98	An intramolecular cascade cyclization of 2-aryl indoles: efficient methods for the construction of 2,3-functionalized indolines and 3-indolinones. *Organic and Biomolecular Chemistry*, **2014**, 12, 3567-71	3.9	10
97	Asymmetric multi-component reactions: convenient access to acyclic stereocenters and functionalized cyclopentenoids. *Tetrahedron: Asymmetry*, **2008**, 19, 1020-1026		10
96	Stereoselective Synthesis of 5--Carbamoylpolyoxamic Acid by [2,3]-Wittig-Still Rearrangement. *Tetrahedron*, **1999**, 55, 13369-13376	2.4	10
95	An Efficient Synthesis of Functionalized Urethanes from Azides. *Journal of the Chemical Society Chemical Communications*, **1992**, 1992, 1308-1310		10
94	A Modified P1 Moiety Enhances In Vitro Antiviral Activity against Various Multidrug-Resistant HIV-1 Variants and In Vitro Central Nervous System Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 7046-7059	5.9	10
93	Potent antiviral HIV-1 protease inhibitor combats highly drug resistant mutant PR20. *Biochemical and Biophysical Research Communications*, **2019**, 519, 61-66	3.4	9
92	Structural studies of antiviral inhibitor with HIV-1 protease bearing drug resistant substitutions of V32I, I47V and V82I. *Biochemical and Biophysical Research Communications*, **2019**, 514, 974-978	3.4	9
91	A novel tricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor, GRL-0739, effectively inhibits the replication of multidrug-resistant HIV-1 variants and has a desirable central nervous system penetration property in vitro. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 2625-35	5.9	9
90	Determination of absolute configuration and binding efficacy of benzimidazole-based FabI inhibitors through the support of electronic circular dichroism and MM-GBSA techniques. *Bioorganic and Medicinal Chemistry Letters*, **2018**, 28, 2074-2079	2.9	9
89	Potent HIV-1 Protease Inhibitors Containing Carboxylic and Boronic Acids: Effect on Enzyme Inhibition and Antiviral Activity and Protein-Ligand X-ray Structural Studies. *ChemMedChem*, **2019**, 14, 1863-1872	3.7	9
88	Asymmetric Syntheses of Potent Antitumor Macrolides Cryptophycin B and Arenastatin A. *European Journal of Organic Chemistry*, **2004**, 2004, 2131-2141	3.2	9

87	Novel Protease Inhibitors Containing C-5-Modified -Tetrahydrofuranylurethane and Aminobenzothiazole as P2 and P2' Ligands That Exert Potent Antiviral Activity against Highly Multidrug-Resistant HIV-1 with a High Genetic Barrier against the Emergence of Drug Resistance. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	8
86	Characterization of a Drosophila ortholog of the Cdc7 kinase: a role for Cdc7 in endoreplication independent of Chiffon. *Journal of Biological Chemistry*, **2015**, 290, 1332-47	5.4	8
85	Structure-Based Design of Highly Potent HIV-1 Protease Inhibitors Containing New Tricyclic Ring P2-Ligands: Design, Synthesis, Biological, and X-ray Structural Studies. *Journal of Medicinal Chemistry*, **2020**, 63, 4867-4879	8.3	8
84	Substituted Bis-THF Protease Inhibitors with Improved Potency against Highly Resistant Mature HIV-1 Protease PR20. *Journal of Medicinal Chemistry*, **2015**, 58, 5088-95	8.3	8
83	Verstkung der Bindung an das Proteinrkgrat ein fruchtbares Konzept gegen die Arzneimittelresistenz von HIV. *Angewandte Chemie*, **2012**, 124, 1812-1838	3.6	8
82	Total syntheses of both enantiomers of amphirionin 4: A chemoenzymatic based strategy for functionalized tetrahydrofurans. *Tetrahedron*, **2017**, 73, 1820-1830	2.4	7
81	Development of an Efficient Enzyme Production and Structure-Based Discovery Platform for BACE1 Inhibitors. *Biochemistry*, **2019**, 58, 4424-4435	3.2	7
80	Novel Central Nervous System (CNS)-Targeting Protease Inhibitors for Drug-Resistant HIV Infection and HIV-Associated CNS Complications. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	7
79	Halogen Bond Interactions of Novel HIV-1 Protease Inhibitors (PI) (GRL-001-15 and GRL-003-15) with the Flap of Protease Are Critical for Their Potent Activity against Wild-Type HIV-1 and Multi-PI-Resistant Variants. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	7
78	Synthesis of Functionalized 4-Methylenetetrahydropyrans by Oxidative Activation of Cinnamyl or Benzyl Ethers. *Tetrahedron Letters*, **2012**, 53, 2568-2570	2	7
77	Lewis Acid Mediated Cyclizations: Diastereoselective Synthesis of Six- to Eight-Membered Substituted Cyclic Ethers. *Synthesis*, **2017**, 49, 4229-4246	2.9	7
76	Synthetic studies of nucleoside antibiotics: a formal synthesis of (+)-sinefungin. *Journal of the Chemical Society Perkin Transactions 1*, **1999**, 1999, 3597-3601		7
75	Activity and structural analysis of GRL-117C: a novel small molecule CCR5 inhibitor active against R5-tropic HIV-1s. *Scientific Reports*, **2019**, 9, 4828	4.9	6
74	Enantioselective Total Syntheses of (+)-Fendleridine and (+)-Acetylaspidoalbidine. *Journal of Organic Chemistry*, **2019**, 84, 5167-5175	4.2	6
73	Enantioselective Synthesis of Dioxatriquinane Structural Motifs for HIV-1 Protease Inhibitors Using a Cascade Radical Cyclization. *Tetrahedron Letters*, **2015**, 56, 3314-3317	2	6
72	Copper-Catalyzed Stille Cross-Coupling Reaction and Application in the Synthesis of the Spliceostatin Core Structure. *Journal of Organic Chemistry*, **2020**, 85, 8111-8120	4.2	6
71	GRL-079, a Novel HIV-1 Protease Inhibitor, Is Extremely Potent against Multidrug-Resistant HIV-1 Variants and Has a High Genetic Barrier against the Emergence of Resistant Variants. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	6
70	Potent HIV-1 protease inhibitors incorporating squaramide-derived P2 ligands: Design, synthesis, and biological evaluation. *Bioorganic and Medicinal Chemistry Letters*, **2019**, 29, 2565-2570	2.9	6

69	A convergent synthesis of carbocyclic sinefungin and its C5 epimer. *European Journal of Organic Chemistry*, **2014**, 2014, 6761-6768	3.2	6
68	Synthesis of Bioactive Natural Products by Asymmetric - and -Aldol Reactions. *Synthesis*, **2009**, 2009, 2992-3002	2.9	6
67	Diastereoselective Synthesis of Substituted Tetrahydropyrans by Copper(II)-Bisphosphine-Catalyzed Olefin Migration and Prins Cyclization. *Synthesis*, **2012**, 44, 3579-3589	2.9	6
66	Darunavir (Prezista): A HIV-1 Protease Inhibitor for Treatment of Multidrug-Resistant HIV **2010**, 29-44		6
65	Stereoselective Synthesis of the C-N Fragment of Griseoviridin. *Synthesis*, **2002**, 2002, 371-374	2.9	6
64	HIV-Associated Neurocognitive Disorder (HAND) and the Prospect of Brain-Penetrating Protease Inhibitors for Antiretroviral Treatment. *Medical Research Archives*, **2017**, 5,	2.1	6
63	Enantioselective Total Synthesis of (+)-Monocerin, a Dihydroisocoumarin Derivative with Potent Antimalarial Properties. *Journal of Organic Chemistry*, **2019**, 84, 6191-6198	4.2	5
62	Design, synthesis, X-ray studies, and biological evaluation of novel macrocyclic HIV-1 protease inhibitors involving the P1'-P2' ligands. *Bioorganic and Medicinal Chemistry Letters*, **2017**, 27, 4925-4931	2.9	5
61	An enantioselective enzymatic desymmetrization route to hexahydro-4-furopyranol, a high-affinity ligand for HIV-1 protease inhibitors. *Tetrahedron Letters*, **2017**, 58, 3230-3233	2	5
60	Metabolism-directed structure optimization of benzimidazole-based Francisella tularensis enoyl-reductase (FabI) inhibitors. *Xenobiotica*, **2014**, 44, 404-16	2	5
59	The FDA Approved HIV-1 Protease Inhibitors for Treatment of HIV/AIDS **2010**, 1-74		5
58	Fluorescent Probes for Monitoring Serine Ubiquitination. *Biochemistry*, **2020**, 59, 1309-1313	3.2	4
57	A Photochemical Route to Optically Active Hexahydro-4-furopyranol, a High-Affinity P2 Ligand for HIV-1 Protease Inhibitors. *Journal of Organic Chemistry*, **2019**, 84, 9801-9805	4.2	4
56	Highly Stereoselective Asymmetric Aldol Routes to -Butyl-2-(3,5-difluorophenyl)-1-oxiran-2-yl)ethyl)carbamates: Building Blocks for Novel Protease Inhibitors. *Tetrahedron Letters*, **2017**, 58, 4062-4065	2	4
55	A fission yeast cell-based system for multidrug resistant HIV-1 proteases. *Cell and Bioscience*, **2017**, 7, 5	9.8	4
54	Darunavir, a New PI with Dual Mechanism: From a Novel Drug Design Concept to New Hope against Drug-Resistant HIV. *Methods and Principles in Medicinal Chemistry*, **2011**, 205-243	0.4	4
53	Highly Selective and Potent Human Secretase 2 (BACE2) Inhibitors against Type 2 Diabetes: Design, Synthesis, X-ray Structure and Structure-Activity Relationship Studies. *ChemMedChem*, **2019**, 14, 545-560	3.7	4
52	Design, Synthesis, and X-ray Studies of Potent HIV-1 Protease Inhibitors with P2-Carboxamide Functionalities. *ACS Medicinal Chemistry Letters*, **2020**, 11, 1965-1972	4.3	3

51	Enantioselective total synthesis of decytospolide A and decytospolide B using an Achmatowicz reaction. *Organic and Biomolecular Chemistry*, **2018**, 16, 5979-5986	3.9	3
50	Design, Synthesis, Biological Evaluation, and X-ray Studies of HIV-1 Protease Inhibitors with Modified P2' Ligands of Darunavir. *ChemMedChem*, **2017**, 12, 1942-1952	3.7	3
49	Evolution of Diverse Classes of Renin Inhibitors through the Years. *Methods and Principles in Medicinal Chemistry*, **2011**, 297-324	0.4	3
48	Enantioselective Total Synthesis of (+)-EBC-23, a Potent Anticancer Agent from the Australian Rainforest. *Journal of Organic Chemistry*, **2021**, 86, 6351-6360	4.2	3
47	An enantioselective synthesis of the C3-C21 segment of the macrolide immunosuppressive agent FR252921. *Tetrahedron Letters*, **2016**, 57, 2884-2887	2	3
46	Synthesis of amide derivatives for electron deficient amines and functionalized carboxylic acids using EDC and DMAP and a catalytic amount of HOBt as the coupling reagents. *Tetrahedron Letters*, **2021**, 63,	2	3
45	Design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors incorporating aminothiochromane and aminotetrahydronaphthalene carboxamide derivatives as the P2 ligands. *European Journal of Medicinal Chemistry*, **2018**, 160, 171-182	6.8	3
44	Structural basis of intron selection by U2 snRNP in the presence of covalent inhibitors. *Nature Communications*, **2021**, 12, 4491	17.4	3
43	Single atom changes in newly synthesized HIV protease inhibitors reveal structural basis for extreme affinity, high genetic barrier, and adaptation to the HIV protease plasticity. *Scientific Reports*, **2020**, 10, 10664	4.9	2
42	Nature Inspired Molecular Design: Stereoselective Synthesis of Bicyclic and Polycyclic Ethers for Potent HIV-1 Protease Inhibitors. *Asian Journal of Organic Chemistry*, **2018**, 7, 1448-1466	3	2
41	Platensimycin and Platencin. *Methods and Principles in Medicinal Chemistry*, **2014**, 271-300	0.4	2
40	HIV-1 Protease Inhibitors for the Treatment of HIV Infection and AIDS: Design of Saquinavir, Indinavir, and Darunavir **2015**, 237-270		2
39	First-Generation HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS. *Methods and Principles in Medicinal Chemistry*, **2011**, 139-168	0.4	2
38	Second-Generation Approved HIV Protease Inhibitors for the Treatment of HIV/AIDS. *Methods and Principles in Medicinal Chemistry*, **2011**, 169-204	0.4	2
37	Fluorine-Modifications Contribute to Potent Antiviral Activity against Highly Drug-Resistant HIV-1 and Favorable Blood-Brain Barrier (BBB) Penetration Property of Novel Central Nervous System (CNS)-targeting HIV-1 Protease Inhibitors .. *Antimicrobial Agents and Chemotherapy*, **2022**, AAC0171521	5.9	2
36	Lewis Acid-Catalyzed Vinyl Acetal Rearrangement of 4,5-Dihydro-1,3-dioxepines: Stereoselective Synthesis of and 2,3-Disubstituted Tetrahydrofurans. *Journal of Organic Chemistry*, **2020**, 85, 10399-10412	4.2	2
35	Spliceostatins and Derivatives: Chemical Syntheses and Biological Properties of Potent Splicing Inhibitors. *Journal of Natural Products*, **2021**, 84, 1681-1706	4.9	2
34	Highly Diastereoselective Intramolecular Asymmetric Oxidopyrylium-olefin [5 + 2] Cycloaddition and Synthesis of 8-Oxabicyclo[3.2.1]oct-3-enone Containing Ring Systems. *Journal of Organic Chemistry*, **2021**, 86, 8127-8142	4.2	2

33	A novel HIV-1 protease inhibitor, GRL-044, has potent activity against various HIV-1s with an extremely high genetic barrier to the emergence of HIV-1 drug resistance. *Global Health & Medicine*, **2019**, 1, 36-48	2.4	2
32	The Chiron Approach to (3,3,6)-Hexahydrofuro[2,3-]furan-3-ol, a Key Subunit of HIV-1 Protease Inhibitor Drug, Darunavir. *Journal of Organic Chemistry*, **2021**, 86, 1216-1222	4.2	2
31	Design, synthesis, X-ray studies, and biological evaluation of novel BACE1 inhibitors with bicyclic isoxazoline carboxamides as the P3 ligand. *Bioorganic and Medicinal Chemistry Letters*, **2018**, 28, 2605-2610	2.9	2
30	Novel HIV PR inhibitors with C4-substituted bis-THF and bis-fluoro-benzyl target the two active site mutations of highly drug resistant mutant PR. *Biochemical and Biophysical Research Communications* , **2021**, 566, 30-35	3.4	2
29	Chloropyridinyl Esters of Nonsteroidal Anti-Inflammatory Agents and Related Derivatives as Potent SARS-CoV-2 3CL Protease Inhibitors. *Molecules*, **2021**, 26,	4.8	2
28	Development of Direct Thrombin Inhibitor, Dabigatran Etexilate, as an Anticoagulant Drug **2015**, 337-354		1
27	Introduction to the Aspartic Proteinase Family. *Methods and Principles in Medicinal Chemistry*, **2011**, 1-21	0.4	1
26	HIV-1 Protease: Role in Viral Replication, Protein□ligand X-Ray Crystal Structures and Inhibitor Design. *Methods and Principles in Medicinal Chemistry*, **2011**, 107-137	0.4	1
25	Discovery and Development of Aliskiren, the First-in-Class Direct Renin Inhibitor for the Treatment of Hypertension. *Methods and Principles in Medicinal Chemistry*, **2011**, 263-296	0.4	1
24	BACE: A (Almost) Perfect Target for Staving off Alzheimer's Disease. *Methods and Principles in Medicinal Chemistry*, **2011**, 391-412	0.4	1
23	Peptidomimetic BACE1 Inhibitors for Treatment of Alzheimer's Disease: Design and Evolution. *Methods and Principles in Medicinal Chemistry*, **2011**, 441-479	0.4	1
22	Nonpeptide BACE1 Inhibitors: Design and Synthesis. *Methods and Principles in Medicinal Chemistry*, **2011**, 481-509	0.4	1
21	Fungal Aspartic Proteases as Possible Therapeutic Targets. *Methods and Principles in Medicinal Chemistry*, **2011**, 573-606	0.4	1
20	Structure-Based Drug Design Strategies for Inhibition of Aspartic Proteinases. *Methods and Principles in Medicinal Chemistry*, **2011**, 71-105	0.4	1
19	Aspartic Proteases: Structure, Function, and Inhibition. *Methods and Principles in Medicinal Chemistry*, **2011**, 23-41	0.4	1
18	Chiral Bis(oxazolines). *Chemistry of Heterocyclic Compounds (New York, 1951): A Series of Monographs*, **2004**, 529-594		1
17	Asymmetric Diels-Alder reaction of 3-(acyloxy) acryloyl oxazolidinones: optically active synthesis of a high-affinity ligand for potent HIV-1 protease inhibitors. *RSC Advances*, **2019**, 9, 41755-41763	3.7	1
16	Design and synthesis of herboxidiene derivatives that potently inhibit splicing. *Organic and Biomolecular Chemistry*, **2021**, 19, 1365-1377	3.9	1

15	Herboxidiene Features That Mediate Conformation-Dependent SF3B1 Interactions to Inhibit Splicing. *ACS Chemical Biology*, **2021**, 16, 520-528	4.9	0
14	A Structure-Based Discovery Platform for BACE2 and the Development of Selective BACE Inhibitors. *ACS Chemical Neuroscience*, **2021**, 12, 581-588	5.7	0
13	Secretase Inhibitors for the Treatment of Alzheimer's Disease: Preclinical and Clinical Inhibitors **2015**, 421-447		
12	From Traditional Medicine to Modern Drugs: Historical Perspective of Structure-Based Drug Design **2015**, 1-18		
11	Design of Inhibitors of Aspartic Acid Proteases **2015**, 19-66		
10	Design of Cysteine Protease Inhibitors **2015**, 131-142		
9	Development of HIV-1 Protease Inhibitors, Antiretroviral Resistance, and Current Challenges of HIV/AIDS Management. *Methods and Principles in Medicinal Chemistry*, **2011**, 245-262	0.4	
8	Secretase: An Unusual Enzyme with Many Possible Disease Targets, Including Alzheimer's Disease. *Methods and Principles in Medicinal Chemistry*, **2011**, 325-351	0.4	
7	Secretase Inhibition: An Overview of Development of Inhibitors for the Treatment of Alzheimer's Disease. *Methods and Principles in Medicinal Chemistry*, **2011**, 353-390	0.4	
6	The Discovery of Secretase and Development toward a Clinical Inhibitor for AD: An Exciting Academic Collaboration. *Methods and Principles in Medicinal Chemistry*, **2011**, 413-440	0.4	
5	The Plasmepsin Family as Antimalarial Drug Targets. *Methods and Principles in Medicinal Chemistry*, **2011**, 511-547	0.4	
4	Plasmepsins Inhibitors as Potential Drugs against Malaria: Starving the Parasite. *Methods and Principles in Medicinal Chemistry*, **2011**, 549-571	0.4	
3	Human Aspartic Proteinases. *Methods and Principles in Medicinal Chemistry*, **2011**, 43-70	0.4	
2	U2 snRNA structure is influenced by SF3A and SF3B proteins but not by SF3B inhibitors. *PLoS ONE*, **2021**, 16, e0258551	3.7	
1	Metabolism-Directed Structure Optimization of Benzimidazole-Based F. Tularensis Enoyl-Reductase (FabI) Inhibitors. *FASEB Journal*, **2013**, 27, 664.3	0.9	